SCHAUMBURG, IL
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)SOCIETY OF UROLOGIC ONCOLOGY CLINICAL TRIALS CONSORTIUM, founded in 2008, is a small nonprofit in the Medical Research sector that reported $684K in total revenue in fiscal year 2024. Revenue surged 24% from the prior year, signaling strong growth momentum. The organization ran a surplus of $371K, a strong 54% operating margin.
THE SOCIETY IS A NATIONAL ALLIANCE OF LEADING ACADEMIC AND COMMUNITY BASED URO-ONCOLOGISTS COMMITTED TO THE FOLLOWING - TO FURTHER UROLOGY RESEARCH AND PHARMACEUTICAL TRIALS, - TO OFFER & PROVIDE FOR THE BEST POSSIBLE APPROACH TO DISEASE EDUCATION AND MANAGEMENT PROVIDING FOR BETTER PATIENT OUTCOMES, - TO PROVIDE EDUCATION FOR THE PROFESSION TO FURTHER THE LEARNINGS CONDUCTED THROUGH THE PROFESSION, - AND TO ALLOW CLINICIANS TO BE AWARE OF EXISTING RESEARCH, WHICH ADVANCES FURTHER CLINICAL EDUCATION AND HYPOTHESES.
THE CONSORTIUM ASSISTS DOCTORS AND HOSPITALS CONDUCTING CLINICAL TRIALS WITH EXPEDITED CONCEPT AND PROTOCOL REVIEW, STANDARDIZED PROTOCOL AND CONTRACT LANGUAGE, AND CENTRALIZED DATA MANAGEMENT TO...
THE CONSORTIUM ASSISTS DOCTORS AND HOSPITALS CONDUCTING CLINICAL TRIALS WITH EXPEDITED CONCEPT AND PROTOCOL REVIEW, STANDARDIZED PROTOCOL AND CONTRACT LANGUAGE, AND CENTRALIZED DATA MANAGEMENT TO HELP TEST NEEDED THERAPIES MORE RAPIDLY THE SUO-CTC DIRECTS REVENUES GENERATED FROM SPONSOR AGREEMENTS TO FUND THE COLLECTIVE ACADEMIC, RESEARCH, CORPORATE AND ADMINISTRATIVE OBJECTIVES OF THE CONSORTIUM IN RETURN THE SUO-CTC OFFERS A VARIETY OF VALUE-ADDED SERVICES WHICH ARE OF SHARED BENEFIT TO THE URO-ONCOLOGY COMMUNITY, PHARMACEUTICAL INDUSTRY BOTH LOCALLY AND ABROAD.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $684,500 | $553,700 | +0.2% |
| Expenses | $313,029 | $270,281 | +0.2% |
| Net Income | $371,471 | $283,419 | +0.3% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Viraj A Master MD PhD FACS | President | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| Brian Matthew Shuch MD | Treasurer | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| Gennady Bratslavsky MD | PAST PRESIDENT | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| Daniel W Lin MD | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Adam Stuart Kibel MD | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Kirsten Lynn Greene MD MS | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Sam S Chang MD MBA | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| W Marston Linehan MD | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Padraic O'Malley MSc MD | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Ms Pam Murphy | Executive Dir. | 1.00 |
Officer
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $684,500 | $313,029 | $1,810,558 | $371,471 |
| 2024 | $553,700 | $270,281 | $1,404,532 | $283,419 |
| 2023 | $332,300 | $237,946 | $1,105,625 | $94,354 |
| 2022 | $626,645 | $183,608 | $1,019,541 | $443,037 |
| 2021 | $219,505 | $154,114 | $560,677 | $65,391 |
| 2020 | $213,800 | $163,220 | $496,527 | $50,580 |
| 2019 | $258,725 | $160,007 | $431,262 | $98,718 |
Compare SOCIETY OF UROLOGIC ONCOLOGY CLINICAL TRIALS CONSORTIUM with other nonprofits in Illinois and across the country.